Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Celecoxib
Drug ID BADD_D00410
Description Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS.[A181544] It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon.[A181532] It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998.[L7604] Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.[A34124]
Indications and Usage Celecoxib is indicated for symptomatic treatment of adult osteoarthritis (OA) and adult rheumatoid arthritis (RA).[L7646] Celecoxib is not a substitute for aspirin for cardiovascular event prophylaxis.[L7646] It may be also be used to treat acute pain from various sources, juvenile rheumatoid arthritis in children over 2, ankylosing spondylitis, and primary dysmenorrhea.[L7646] Celecoxib, in combination with [tramadol], is indicated for the management of acute pain in adults severe enough to require an opioid analgesic and in whom alternative treatments are inadequate.[L38949]
Marketing Status approved; investigational
ATC Code L01XX33; M01AH01
DrugBank ID DB00482
KEGG ID D00567
MeSH ID D000068579
PubChem ID 2662
TTD Drug ID D03RTS
NDC Product Code 77771-159; 80425-0167; 80425-0281; 0591-3985; 51552-1461; 53104-7533; 66651-919; 13668-310; 33342-156; 33342-157; 42571-145; 57582-212; 0025-1520; 61919-682; 62135-023; 63187-562; 65862-910; 68071-2626; 70518-3424; 0591-3982; 71335-2019; 71610-283; 75834-239; 76420-009; 76420-243; 80425-0038; 51927-5063; 54245-3392; 57582-032; 62512-0018; 65862-793; 16714-733; 42806-721; 43063-967; 46708-267; 50436-3984; 57582-211; 59762-1517; 67296-1847; 68071-4642; 69367-302; 70247-006; 71205-027; 71205-664; 0591-3983; 75834-237; 81288-021; 81288-023; 0591-3984; 55111-898; 65427-002; 65977-0052; 77777-115; 42571-143; 50090-4789; 50090-5178; 50228-159; 57582-214; 0025-1525; 68180-398; 70518-3204; 70518-3733; 71335-0292; 71335-1066; 72189-360; 72241-023; 55154-7646; 60687-447; 62135-021; 62135-022; 63187-301; 68071-2776; 68180-395; 68788-8197; 69117-0023; 70247-009; 71209-056; 75834-238; 77771-156; 80425-0040; 16714-732; 43063-825; 45865-970; 46708-269; 46708-270; 50268-168; 53002-2338; 59762-1516; 60505-3847; 60505-3849; 61919-360; 62332-141; 63187-079; 63629-3021; 63629-8156; 68071-2733; 69367-301; 70518-3292; 72789-259; 75834-236; 80425-0323; 81288-022; 47621-024; 65691-0048; 68724-1004; 0093-7166; 0093-7170; 50090-5638; 50436-3982; 51990-033; 60687-436; 60760-742; 61919-837; 62332-143; 63187-643; 65162-817; 65162-819; 68788-8206; 69097-422; 69097-423; 70518-1346; 71205-055; 71335-1804; 0615-8338; 72241-022; 72567-001; 80425-0096; 13668-441; 0093-7165; 33342-155; 42806-720; 45865-943; 50268-169; 62332-140; 65162-820; 65862-907; 67296-1600; 69117-0021; 70518-2748; 70934-469; 71209-054; 71335-0936; 80425-0142; 80425-0209; 64552-4032; 13668-442; 16714-731; 16714-734; 29300-157; 29300-374; 42571-144; 50228-158; 50436-3983; 51655-059; 51990-034; 55154-7645; 55700-613; 0025-1515; 59762-1515; 59762-1518; 60505-3848; 60760-649; 60760-823; 65162-818; 65862-908; 67296-1345; 71209-055; 72241-024; 72241-025; 77771-157; 0904-6502; 58159-067; 68981-025; 29300-158; 43063-669; 46708-268; 51655-437; 57582-213; 59385-055; 0025-1530; 60760-824; 62332-142; 65862-909; 67296-1608; 68180-399; 68788-7286; 69097-420; 69097-421; 69117-0020; 70247-007; 70247-008; 70934-978; 71209-057; 71335-0868; 80425-0037; 80425-0039; 80425-0321; 49706-1880; 62704-0046; 65015-882; 72761-022; 13668-307; 0093-7306; 29300-373; 42571-142; 42806-723; 43353-257; 50090-6380; 50228-156; 50228-157; 63187-633; 68180-396; 68788-7264; 69117-0022; 70518-2922; 71205-020; 71205-439; 71610-584; 72189-123; 77771-158; 81288-020; 0904-6503; 43744-071; 52048-1995; 33342-158; 42806-722; 51655-060; 51655-436; 51990-035; 53002-1338; 55700-607
UNII JCX84Q7J1L
Synonyms Celecoxib | 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide | Celebrex | SC 58635 | SC-58635 | SC58635
Chemical Information
Molecular Formula C17H14F3N3O2S
CAS Registry Number 169590-42-5
SMILES CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Lower gastrointestinal haemorrhage07.12.03.011; 24.07.02.0300.000075%
Deep vein thrombosis24.01.02.003--Not Available
Self-injurious ideation19.12.01.007--Not Available
Systemic inflammatory response syndrome08.01.05.005; 24.06.03.008; 10.02.01.0080.000075%Not Available
Large intestine polyp16.05.02.006; 07.20.01.010--Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.0150.000099%Not Available
Conjunctival hyperaemia06.04.01.0040.000050%Not Available
Ocular discomfort06.08.03.0080.000109%Not Available
Lymphatic disorder01.09.01.003--Not Available
Eosinophilic pneumonia acute01.02.04.004; 22.01.01.0080.000050%Not Available
Cardiac flutter02.03.02.0120.000050%Not Available
Musculoskeletal stiffness15.03.05.0270.001313%Not Available
Protein urine present13.13.02.006--Not Available
Epigastric discomfort07.01.02.0040.000050%Not Available
Musculoskeletal discomfort15.03.04.0010.000124%Not Available
Organ failure08.01.03.041--Not Available
Febrile bone marrow aplasia08.05.02.005; 01.03.03.0070.000075%Not Available
Skin swelling23.03.03.0390.000134%Not Available
Injection site swelling08.02.03.017; 12.07.03.018--Not Available
Secretion discharge08.01.03.019--Not Available
Infusion site swelling12.07.05.003; 08.02.05.0020.000134%Not Available
Type IV hypersensitivity reaction10.01.03.0220.000050%Not Available
Helicobacter infection11.02.18.001--Not Available
Vanishing bile duct syndrome09.02.03.0030.000174%Not Available
Skin burning sensation23.03.03.021; 17.02.06.009--Not Available
Haemorrhoidal haemorrhage24.10.02.001; 07.15.03.002--
Transaminases increased13.03.04.036--Not Available
Dysphemia19.19.03.005; 17.02.08.010--Not Available
Haemorrhage24.07.01.0020.000965%Not Available
Cutaneous lupus erythematosus15.06.02.007; 10.04.03.007; 23.03.02.0080.000050%Not Available
The 19th Page    First    Pre   19 20 21 22 23    Next   Last    Total 24 Pages